TY - JOUR
T1 - A tale of two receptors:Insulin and insulin-like growth factor signaling in cancer
AU - Yee, Douglas
N1 - Publisher Copyright:
© -2014 American Association for Cancer Research.
PY - 2015/2/15
Y1 - 2015/2/15
N2 - Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. See related articles by Jones et al., p. 693, and Puzanov et al., p.
AB - Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. See related articles by Jones et al., p. 693, and Puzanov et al., p.
UR - http://www.scopus.com/inward/record.url?scp=84923124115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923124115&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-2056
DO - 10.1158/1078-0432.CCR-14-2056
M3 - Article
C2 - 25303978
AN - SCOPUS:84923124115
SN - 1078-0432
VL - 21
SP - 667
EP - 669
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -
